Last reviewed · How we verify
NCT03513055
Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus
NA trial testing nurse inject premixed insulin in Type2 Diabetes Mellitus in 60 participants. Status unknown.
30 September 2018
Quick facts
| Lead sponsor | Nanjing First Hospital, Nanjing Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 7 May 2018 |
| Primary completion | 30 September 2018 |
| Estimated completion | 30 September 2018 |
Drugs / interventions tested
- nurse inject premixed insulin
Conditions studied
- Type2 Diabetes Mellitus — all drugs for Type2 Diabetes Mellitus →
Sponsor
Nanjing First Hospital, Nanjing Medical University
Who can join
Adults 18 to 80, any sex, with Type2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare patients and nurses using insulin pen injector to inject premixed insulin respectively, using continuous glucose monitoring system to evaluate the glucose excursion in the two sets, study the relationship between glucose excursion and inject technique in type 2 diabetes mellitus.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Insulin Injection Technique is Associated with Glycemic Variability in Patients with Type 2 Diabetes.
Yuan L, Li F, Jing T, Ding B, et al · · 2018 · cited 13× · PMID 30341664 · DOI 10.1007/s13300-018-0522-1
Verify or expand the search:
- PubMed search for NCT03513055
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type2 Diabetes Mellitus
Currently open trials in the same condition.
- NCT07533604 — SnapDandCGMinType2Diabetes · NA · recruiting
- NCT06961019 — Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets · NA · recruiting
- NCT06497842 — Effort During Resistance Training in Type 2 Diabetes · NA · active not recruiting
- NCT06257966 — A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type · Phase 3 · active not recruiting
- NCT03647306 — Behavioral Chronotype: Impact on Sleep and Metabolism · NA · active not recruiting
Other Nanjing First Hospital, Nanjing Medical University trials
Trials by the same sponsor.
- NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
- NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
- NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
- NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
- NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03513055 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
- Last refreshed: 11 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03513055.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing